{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T21:24:52Z","timestamp":1792790692408,"version":"4.5.0"},"reference-count":89,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,1,17]],"date-time":"2026-01-17T00:00:00Z","timestamp":1768608000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,1,30]],"date-time":"2026-01-30T00:00:00Z","timestamp":1769731200000},"content-version":"vor","delay-in-days":13,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"National Health and Medical Research Council (NHMRC) Medical Research Future Fund","award":["APP2013957"],"award-info":[{"award-number":["APP2013957"]}],"id":[{"id":"https:\/\/ror.org\/011kf5r70","id-type":"ROR","asserted-by":"crossref"}]},{"name":"National Health and Medical Research Council (NHMRC) Medical Research Future Fund","award":["APP2013957"],"award-info":[{"award-number":["APP2013957"]}],"id":[{"id":"https:\/\/ror.org\/011kf5r70","id-type":"ROR","asserted-by":"crossref"}]},{"name":"National Health and Medical Research Council (NHMRC) Medical Research Future Fund","award":["APP2013957"],"award-info":[{"award-number":["APP2013957"]}],"id":[{"id":"https:\/\/ror.org\/011kf5r70","id-type":"ROR","asserted-by":"crossref"}]},{"name":"National Health and Medical Research Council (NHMRC) Medical Research Future Fund","award":["APP2013957"],"award-info":[{"award-number":["APP2013957"]}],"id":[{"id":"https:\/\/ror.org\/011kf5r70","id-type":"ROR","asserted-by":"crossref"}]},{"name":"National Health and Medical Research Council (NHMRC) Medical Research Future Fund","award":["APP2013957"],"award-info":[{"award-number":["APP2013957"]}],"id":[{"id":"https:\/\/ror.org\/011kf5r70","id-type":"ROR","asserted-by":"crossref"}]},{"name":"National Health and Medical Research Council (NHMRC) Medical Research Future Fund","award":["APP2013957"],"award-info":[{"award-number":["APP2013957"]}],"id":[{"id":"https:\/\/ror.org\/011kf5r70","id-type":"ROR","asserted-by":"crossref"}]},{"name":"National Health and Medical Research Council (NHMRC) Medical Research Future Fund","award":["APP2013957"],"award-info":[{"award-number":["APP2013957"]}],"id":[{"id":"https:\/\/ror.org\/011kf5r70","id-type":"ROR","asserted-by":"crossref"}]},{"name":"National Health and Medical Research Council (NHMRC) Medical Research Future Fund","award":["APP2013957"],"award-info":[{"award-number":["APP2013957"]}],"id":[{"id":"https:\/\/ror.org\/011kf5r70","id-type":"ROR","asserted-by":"crossref"}]},{"name":"National Health and Medical Research Council (NHMRC) Medical Research Future Fund","award":["APP2013957"],"award-info":[{"award-number":["APP2013957"]}],"id":[{"id":"https:\/\/ror.org\/011kf5r70","id-type":"ROR","asserted-by":"crossref"}]},{"name":"National Health and Medical Research Council (NHMRC) Medical Research Future Fund","award":["APP2013957"],"award-info":[{"award-number":["APP2013957"]}],"id":[{"id":"https:\/\/ror.org\/011kf5r70","id-type":"ROR","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001349","name":"Singapore National Medical Research Council","doi-asserted-by":"crossref","award":["STPRG-FY19-001, COVID19RF-003 and OFLCG19-May-0034"],"award-info":[{"award-number":["STPRG-FY19-001, COVID19RF-003 and OFLCG19-May-0034"]}],"id":[{"id":"10.13039\/501100001349","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001349","name":"Singapore National Medical Research Council","doi-asserted-by":"crossref","award":["STPRG-FY19-001, COVID19RF-003 and OFLCG19-May-0034"],"award-info":[{"award-number":["STPRG-FY19-001, COVID19RF-003 and OFLCG19-May-0034"]}],"id":[{"id":"10.13039\/501100001349","id-type":"DOI","asserted-by":"crossref"}]},{"name":"NHMRC Senior Research Fellowship","award":["1117766"],"award-info":[{"award-number":["1117766"]}]},{"name":"NHMRC Investigator Grant","award":["2008913"],"award-info":[{"award-number":["2008913"]}]},{"name":"NHMRC Ideas grant","award":["APP1181580"],"award-info":[{"award-number":["APP1181580"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["npj Vaccines"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Whilst COVID vaccines proved to be effective in preventing severe COVID disease, they failed to control the emergence of variant viruses and antibody responses waned quickly. We report the findings of a recombinant \u03b2-SARS-CoV-2 variant virus-like particle (VLP) vaccine composed of the viral spike (S), membrane (M) and envelope (E) proteins produced in Vero cell factories. The \u03b2-SARS-CoV-2 VLP vaccine formulated with Addavax or MF59 produced strong antibody and CD4\u2009+\u2009T cell responses and was protective in mice against pulmonary infection with Beta, Delta and Omicron BA.5 variant viruses. Multiplex RBD-ACE2 binding inhibition assay was performed as a surrogate virus neutralisation test and revealed immune sera from immunised mice produced low-titre broad-inhibitory anti-RBD-ACE2 antibodies (sNAb) to Alpha, Delta, Beta, Gamma, Mu, Omicron BA.1, BA.2, BA.5 and XBB1.5. However, microneutralisation assays did not show the presence of sNAb. The \u03b2-SARS-CoV-2 VLP is strongly immunogenic producing broad antibody and T cell responses and is protective against infection with SARS-CoV-2 variant viruses.<\/jats:p>","DOI":"10.1038\/s41541-025-01355-y","type":"journal-article","created":{"date-parts":[[2026,1,17]],"date-time":"2026-01-17T05:54:17Z","timestamp":1768629257000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Preclinical development of a cross-protective \u03b2-SARS-CoV-2 virus-like particle vaccine adjuvanted with MF59"],"prefix":"10.1038","volume":"11","author":[{"given":"Linda","family":"Earnest","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel Fernandez","family":"Ruiz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melissa A.","family":"Edeling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julio Carrera","family":"Montoya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashley Huey Yiing","family":"Yap","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chinn Yi","family":"Wong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lauren E.","family":"Holz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie","family":"Gras","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon","family":"Collett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James P.","family":"Cooney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathryn C.","family":"Davidson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samantha L.","family":"Grimley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Damian F. J.","family":"Purcell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason","family":"Roberts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jamie","family":"Mumford","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chee Wah","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin-Fa","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dale I.","family":"Godfrey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Frieman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dhiraj","family":"Hans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth","family":"Vincan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danielle E.","family":"Anderson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kanta","family":"Subbarao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Pellegrini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason M.","family":"Mackenzie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven","family":"Rockman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William R.","family":"Heath","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph","family":"Torresi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,17]]},"reference":[{"key":"1355_CR1","doi-asserted-by":"publisher","unstructured":"Wang, P. et al. Increased resistance of SARS-CoV-2 Variants B.1.351 and B.1.1.7 to antibody neutralization. https:\/\/doi.org\/10.1101\/2021.1101.1125.428137 (2021).","DOI":"10.1101\/2021.1101.1125.428137"},{"key":"1355_CR2","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1038\/s41586-021-03426-1","volume":"593","author":"NG Davies","year":"2021","unstructured":"Davies, N. G. et al. Increased mortality in community-tested cases of SARS-CoV-2 lineage B.1.1.7. Nature 593, 270\u2013274 (2021).","journal-title":"Nature"},{"key":"1355_CR3","doi-asserted-by":"publisher","first-page":"1518","DOI":"10.1016\/j.chom.2022.09.015","volume":"30","author":"P Qu","year":"2022","unstructured":"Qu, P. et al. Evasion of neutralizing antibody responses by the SARS-CoV-2 BA.2.75 variant. Cell Host Microbe 30, 1518\u20131526 e1514 (2022).","journal-title":"Cell Host Microbe"},{"key":"1355_CR4","doi-asserted-by":"publisher","first-page":"2094","DOI":"10.1056\/NEJMc2211845","volume":"387","author":"E Takashita","year":"2022","unstructured":"Takashita, E. et al. In vitro efficacy of antiviral agents against omicron subvariant BA.4.6. N. Engl. J. Med. 387, 2094\u20132097 (2022).","journal-title":"N. Engl. J. Med."},{"key":"1355_CR5","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/S1473-3099(22)00733-2","volume":"23","author":"P Arora","year":"2023","unstructured":"Arora, P. et al. Omicron sublineage BQ.1.1 resistance to monoclonal antibodies. Lancet Infect. Dis. 23, 22\u201323 (2023).","journal-title":"Lancet Infect. Dis."},{"key":"1355_CR6","doi-asserted-by":"publisher","unstructured":"Voysey, M. et al. Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials. Lancet. https:\/\/doi.org\/10.1016\/S0140-6736(21)00432-3 (2021).","DOI":"10.1016\/S0140-6736(21)00432-3"},{"key":"1355_CR7","doi-asserted-by":"publisher","first-page":"2603","DOI":"10.1056\/NEJMoa2034577","volume":"383","author":"FP Polack","year":"2020","unstructured":"Polack, F. P. et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N. Engl. J. Med. 383, 2603\u20132615 (2020).","journal-title":"N. Engl. J. Med."},{"key":"1355_CR8","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1016\/S1473-3099(22)00816-7","volume":"23","author":"R Uraki","year":"2023","unstructured":"Uraki, R. et al. Humoral immune evasion of the omicron subvariants BQ.1.1 and XBB. Lancet Infect. Dis. 23, 30\u201332 (2023).","journal-title":"Lancet Infect. Dis."},{"key":"1355_CR9","doi-asserted-by":"publisher","unstructured":"Kurhade, C. et al. Low neutralization of SARS-CoV-2 Omicron BA.2.75.2, BQ.1.1, and XBB.1 by parental mRNA vaccine or a BA.5-bivalent booster. Nat. Med. https:\/\/doi.org\/10.1038\/s41591-022-02162-x (2022).","DOI":"10.1038\/s41591-022-02162-x"},{"key":"1355_CR10","doi-asserted-by":"publisher","first-page":"2254","DOI":"10.1038\/s41467-024-46490-7","volume":"15","author":"D Planas","year":"2024","unstructured":"Planas, D. et al. Distinct evolution of SARS-CoV-2 Omicron XBB and BA.2.86\/JN.1lineages combining increased fitness and antibody evasion. Nat. Commun. 15, 2254 (2024).","journal-title":"Nat. Commun."},{"key":"1355_CR11","doi-asserted-by":"publisher","first-page":"e70","DOI":"10.1016\/S1473-3099(23)00744-2","volume":"24","author":"S Yang","year":"2024","unstructured":"Yang, S. et al. Fast evolution of SARS-CoV-2 BA.2.86 to JN.1 under heavy immune pressure. Lancet Infect. Dis. 24, e70\u2013e72 (2024).","journal-title":"Lancet Infect. Dis."},{"key":"1355_CR12","doi-asserted-by":"publisher","first-page":"854","DOI":"10.1056\/NEJMc2214916","volume":"388","author":"J Zou","year":"2023","unstructured":"Zou, J. et al. Neutralization of BA.4-BA.5, BA.4.6, BA.2.75.2, BQ.1.1, and XBB.1with Bivalent Vaccine. N Engl. J. Med. 388, 854\u2013857 (2023).","journal-title":"N Engl. J. Med."},{"key":"1355_CR13","doi-asserted-by":"publisher","unstructured":"Chalkias, S. et al. Three-month antibody persistence of a bivalent omicron-containing booster vaccine against COVID-19. Res. Sq. https:\/\/doi.org\/10.21203\/rs.3.rs-2239682\/v1 (2022).","DOI":"10.21203\/rs.3.rs-2239682\/v1"},{"key":"1355_CR14","doi-asserted-by":"publisher","unstructured":"Wang, Q. et al. Antibody response to omicron BA.4-BA.5 bivalent booster. N. Engl. J. Med. https:\/\/doi.org\/10.1056\/NEJMc2213907 (2023).","DOI":"10.1056\/NEJMc2213907"},{"key":"1355_CR15","doi-asserted-by":"publisher","unstructured":"Collier, A. Y. et al. Immunogenicity of BA.5 Bivalent mRNA vaccine boosters. N. Engl. J. Med. https:\/\/doi.org\/10.1056\/NEJMc2213948 (2023).","DOI":"10.1056\/NEJMc2213948"},{"key":"1355_CR16","doi-asserted-by":"publisher","unstructured":"Fabiani, M. et al. Protection against severe COVID-19 after second booster dose of adapted bivalent (original\/Omicron BA.4-5) mRNA vaccine in persons >\/=60 years, by time since infection, Italy, 12 September to 11 December 2022. Euro Surveill. 28. https:\/\/doi.org\/10.2807\/1560-7917.ES.2023.28.8.2300105 (2023).","DOI":"10.2807\/1560-7917.ES.2023.28.8.2300105"},{"key":"1355_CR17","doi-asserted-by":"publisher","first-page":"e128","DOI":"10.1016\/S1473-3099(25)00015-5","volume":"25","author":"J Liu","year":"2025","unstructured":"Liu, J. et al. Virological and antigenic characteristics of SARS-CoV-2 variants LF.7.2.1, NP.1, and LP.8.1. Lancet Infect. Dis. 25, e128\u2013e130 (2025).","journal-title":"Lancet Infect. Dis."},{"key":"1355_CR18","doi-asserted-by":"publisher","first-page":"e374","DOI":"10.1016\/S1473-3099(25)00308-1","volume":"25","author":"C Guo","year":"2025","unstructured":"Guo, C. et al. Antigenic and virological characteristics of SARS-CoV-2 variants BA.3.2, XFG, and NB.1.8.1. Lancet Infect. Dis. 25, e374\u2013e377 (2025).","journal-title":"Lancet Infect. Dis."},{"key":"1355_CR19","doi-asserted-by":"publisher","DOI":"10.1186\/s13690-022-00935-x","volume":"80","author":"IY Addo","year":"2022","unstructured":"Addo, I. Y., Dadzie, F. A., Okeke, S. R., Boadi, C. & Boadu, E. F. Duration of immunity following full vaccination against SARS-CoV-2: a systematic review. Arch. Public Health 80, 200 (2022).","journal-title":"Arch. Public Health"},{"key":"1355_CR20","doi-asserted-by":"publisher","first-page":"96","DOI":"10.2105\/AJPH.2022.307112","volume":"113","author":"W Tu","year":"2023","unstructured":"Tu, W. et al. SARS-CoV-2 infection, hospitalization, and death in vaccinated and infected individuals by age groups in Indiana, 2021\u20122022. Am. J. Public Health 113, 96\u2013104 (2023).","journal-title":"Am. J. Public Health"},{"key":"1355_CR21","doi-asserted-by":"publisher","first-page":"714","DOI":"10.1016\/S2213-2600(24)00179-6","volume":"12","author":"MMI Mesle","year":"2024","unstructured":"Mesle, M. M. I. et al. Estimated number of lives directly saved by COVID-19 vaccination programmes in the WHO European Region from December, 2020, to March, 2023: a retrospective surveillance study. Lancet Respir. Med. 12, 714\u2013727 (2024).","journal-title":"Lancet Respir. Med."},{"key":"1355_CR22","doi-asserted-by":"publisher","first-page":"73","DOI":"10.15585\/mmwr.mm7406a1","volume":"74","author":"R Link-Gelles","year":"2025","unstructured":"Link-Gelles, R. et al. Interim estimates of 2024-2025 COVID-19 vaccine effectiveness among adults aged >\/=18 Years\u2014VISION and IVY networks, September 2024\u2013January 2025. Morb. Mortal. Wkly Rep. 74, 73\u201382 (2025).","journal-title":"Morb. Mortal. Wkly Rep."},{"key":"1355_CR23","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1038\/s41586-022-04865-0","volume":"607","author":"RK Suryawanshi","year":"2022","unstructured":"Suryawanshi, R. K. et al. Limited cross-variant immunity from SARS-CoV-2 Omicron without vaccination. Nature 607, 351\u2013355 (2022).","journal-title":"Nature"},{"key":"1355_CR24","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2023.1065609","volume":"14","author":"S Collett","year":"2023","unstructured":"Collett, S. et al. Development of virus-like particles with inbuilt immunostimulatory properties as vaccine candidates. Front. Microbiol. 14, 1065609 (2023).","journal-title":"Front. Microbiol."},{"key":"1355_CR25","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1016\/j.cell.2020.08.017","volume":"183","author":"T Sekine","year":"2020","unstructured":"Sekine, T. et al. Robust T cell immunity in convalescent individuals with asymptomatic or mild COVID-19. Cell 183, 158\u2013168 e114 (2020).","journal-title":"Cell"},{"key":"1355_CR26","doi-asserted-by":"publisher","first-page":"1489","DOI":"10.1016\/j.cell.2020.05.015","volume":"181","author":"A Grifoni","year":"2020","unstructured":"Grifoni, A. et al. Targets of T cell responses to SARS-CoV-2 coronavirus in humans with COVID-19 disease and unexposed individuals. Cell 181, 1489\u20131501 e1415 (2020).","journal-title":"Cell"},{"key":"1355_CR27","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1016\/j.cell.2021.01.007","volume":"184","author":"A Sette","year":"2021","unstructured":"Sette, A. & Crotty, S. Adaptive immunity to SARS-CoV-2 and COVID-19. Cell 184, 861\u2013880 (2021).","journal-title":"Cell"},{"key":"1355_CR28","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1016\/j.cell.2022.01.015","volume":"185","author":"A Tarke","year":"2022","unstructured":"Tarke, A. et al. SARS-CoV-2 vaccination induces immunological T cell memory able to cross-recognize variants from Alpha to Omicron. Cell 185, 847\u2013859 e811 (2022).","journal-title":"Cell"},{"key":"1355_CR29","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1038\/s41586-023-06331-x","volume":"620","author":"DG Augusto","year":"2023","unstructured":"Augusto, D. G. et al. A common allele of HLA is associated with asymptomatic SARS-CoV-2 infection. Nature 620, 128\u2013136 (2023).","journal-title":"Nature"},{"key":"1355_CR30","doi-asserted-by":"publisher","first-page":"1279","DOI":"10.1056\/NEJMoa2208343","volume":"387","author":"S Chalkias","year":"2022","unstructured":"Chalkias, S. et al. A bivalent omicron-containing booster vaccine against Covid-19. N. Engl. J. Med. 387, 1279\u20131291 (2022).","journal-title":"N. Engl. J. Med."},{"key":"1355_CR31","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1038\/s41392-022-01123-7","volume":"7","author":"Q Li","year":"2022","unstructured":"Li, Q. et al. Cross-reactivity of eight SARS-CoV-2 variants rationally predicts immunogenicity clustering in sarbecoviruses. Signal Transduct. Target. Ther. 7, 256 (2022).","journal-title":"Signal Transduct. Target. Ther."},{"key":"1355_CR32","doi-asserted-by":"publisher","DOI":"10.1128\/jvi.00558-22","volume":"96","author":"T Moyo-Gwete","year":"2022","unstructured":"Moyo-Gwete, T. et al. Shared N417-dependent epitope on the SARS-CoV-2 Omicron, Beta, and Delta Plus variants. J. Virol. 96, e0055822 (2022).","journal-title":"J. Virol."},{"key":"1355_CR33","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1056\/NEJMc2206711","volume":"387","author":"O Launay","year":"2022","unstructured":"Launay, O. et al. Immunogenicity and safety of beta-adjuvanted recombinant booster vaccine. N. Engl. J. Med 387, 374\u2013376 (2022).","journal-title":"N. Engl. J. Med"},{"key":"1355_CR34","doi-asserted-by":"publisher","first-page":"2025","DOI":"10.1038\/s41591-021-01527-y","volume":"27","author":"A Choi","year":"2021","unstructured":"Choi, A. et al. Safety and immunogenicity of SARS-CoV-2 variant mRNA vaccine boosters inhealthy adults: an interim analysis. Nat. Med. 27, 2025\u20132531 (2021).","journal-title":"Nat. Med."},{"key":"1355_CR35","doi-asserted-by":"publisher","first-page":"5556","DOI":"10.1016\/j.csbj.2021.10.004","volume":"19","author":"A Klinakis","year":"2021","unstructured":"Klinakis, A., Cournia, Z. & Rampias, T. N-terminal domain mutations of the spike protein are structurally implicated in epitope recognition in emerging SARS-CoV-2 strains. Comput. Struct. Biotechnol. J. 19, 5556\u20135567 (2021).","journal-title":"Comput. Struct. Biotechnol. J."},{"key":"1355_CR36","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1126\/science.abq3773","volume":"377","author":"C Dacon","year":"2022","unstructured":"Dacon, C. et al. Broadly neutralizing antibodies target the coronavirus fusion peptide. Science 377, 728\u2013735 (2022).","journal-title":"Science"},{"key":"1355_CR37","doi-asserted-by":"publisher","unstructured":"Edeling, M. A. et al. Development of methods to produce SARS-CoV-2 virus-like particles at scale. Biotechnol. Bioeng. https:\/\/doi.org\/10.1002\/bit.28937 (2025).","DOI":"10.1002\/bit.28937"},{"key":"1355_CR38","doi-asserted-by":"publisher","first-page":"1501","DOI":"10.1126\/science.abd0826","volume":"369","author":"CL Hsieh","year":"2020","unstructured":"Hsieh, C. L. et al. Structure-based design of prefusion-stabilized SARS-CoV-2 spikes. Science 369, 1501\u20131505 (2020).","journal-title":"Science"},{"key":"1355_CR39","doi-asserted-by":"publisher","first-page":"0","DOI":"10.3390\/organoids3010002","volume":"3","author":"J Carrera Montoya","year":"2024","unstructured":"Carrera Montoya, J. et al. Human nasal epithelium organoids for assessing neutralizing antibodies to a protective SARS-CoV-2 virus-like particle vaccine. Organoids 3, 0\u201313 (2024).","journal-title":"Organoids"},{"key":"1355_CR40","unstructured":"Melbourne, T. U. o. Stabilised virus-like particles and uses there of. Australian Provisional Patent Application No. 2024903881 (2024)."},{"key":"1355_CR41","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1021\/acs.biochem.3c00437","volume":"63","author":"JA Townsend","year":"2024","unstructured":"Townsend, J. A. et al. Differences in oligomerization of the SARS-CoV-2 envelope protein, poliovirus VP4, and HIV Vpu. Biochemistry 63, 241\u2013250 (2024).","journal-title":"Biochemistry"},{"key":"1355_CR42","doi-asserted-by":"publisher","first-page":"1202","DOI":"10.1038\/s41594-020-00536-8","volume":"27","author":"VS Mandala","year":"2020","unstructured":"Mandala, V. S. et al. Structure and drug binding of the SARS-CoV-2 envelope protein transmembrane domain in lipid bilayers. Nat. Struct. Mol. Biol. 27, 1202\u20131208 (2020).","journal-title":"Nat. Struct. Mol. Biol."},{"key":"1355_CR43","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.1038\/s42003-023-05490-x","volume":"6","author":"R Zhang","year":"2023","unstructured":"Zhang, R. et al. Dimeric transmembrane structure of the SARS-CoV-2 E protein. Commun. Biol. 6, 1109 (2023).","journal-title":"Commun. Biol."},{"key":"1355_CR44","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.1038\/s41587-020-0631-z","volume":"38","author":"CW Tan","year":"2020","unstructured":"Tan, C. W. et al. A SARS-CoV-2 surrogate virus neutralization test based on antibody-mediated blockage of ACE2-spike protein-protein interaction. Nat. Biotechnol. 38, 1073\u20131078 (2020).","journal-title":"Nat. Biotechnol."},{"key":"1355_CR45","doi-asserted-by":"publisher","first-page":"1401","DOI":"10.1056\/NEJMoa2108453","volume":"385","author":"CW Tan","year":"2021","unstructured":"Tan, C. W. et al. Pan-sarbecovirus neutralizing antibodies in BNT162b2-immunized SARS-CoV-1 survivors. N. Engl. J. Med. 385, 1401\u20131406 (2021).","journal-title":"N. Engl. J. Med."},{"key":"1355_CR46","doi-asserted-by":"publisher","unstructured":"Zhuang, Z. et al. Mapping and role of T cell response in SARS-CoV-2-infected mice. J. Exp. Med. 218. https:\/\/doi.org\/10.1084\/jem.20202187 (2021).","DOI":"10.1084\/jem.20202187"},{"key":"1355_CR47","doi-asserted-by":"publisher","first-page":"e1009163","DOI":"10.1371\/journal.ppat.1009163","volume":"16","author":"M Hassert","year":"2020","unstructured":"Hassert, M. et al. mRNA-induced expression of human angiotensin-converting enzyme 2 in mice for the study of the adaptive immune response to severe acute respiratory syndrome coronavirus 2. PLoS Pathog. 16, e1009163 (2020).","journal-title":"PLoS Pathog."},{"key":"1355_CR48","doi-asserted-by":"publisher","unstructured":"van Bergen, J. et al. Multiantigen pan-sarbecovirus DNA vaccines generate protective T cell immune responses. JCI Insight 8. https:\/\/doi.org\/10.1172\/jci.insight.172488 (2023).","DOI":"10.1172\/jci.insight.172488"},{"key":"1355_CR49","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2118312119","volume":"119","author":"B Kingstad-Bakke","year":"2022","unstructured":"Kingstad-Bakke, B. et al. Vaccine-induced systemic and mucosal T cell immunity to SARS-CoV-2 viral variants. Proc. Natl. Acad. Sci. USA 119, e2118312119 (2022).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"1355_CR50","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2022.840757","volume":"13","author":"F Tarres-Freixas","year":"2022","unstructured":"Tarres-Freixas, F. et al. Heterogeneous infectivity and pathogenesis of SARS-CoV-2 variants Beta, Delta and Omicron in transgenic K18-hACE2 and wildtype mice. Front. Microbiol. 13, 840757 (2022).","journal-title":"Front. Microbiol."},{"key":"1355_CR51","doi-asserted-by":"publisher","DOI":"10.1016\/j.isci.2021.102699","volume":"24","author":"EN Gary","year":"2021","unstructured":"Gary, E. N. et al. A novel mouse AAV6 hACE2 transduction model of wild-type SARS-CoV-2 infection studied using synDNA immunogens. iScience 24, 102699 (2021).","journal-title":"iScience"},{"key":"1355_CR52","doi-asserted-by":"publisher","first-page":"2433","DOI":"10.1080\/22221751.2020.1838955","volume":"9","author":"R Rathnasinghe","year":"2020","unstructured":"Rathnasinghe, R. et al. Comparison of transgenic and adenovirus hACE2 mouse models for SARS-CoV-2 infection. Emerg. Microbes Infect. 9, 2433\u20132445 (2020).","journal-title":"Emerg. Microbes Infect."},{"key":"1355_CR53","doi-asserted-by":"publisher","unstructured":"Tailor, N. et al. Generation and characterization of a SARS-CoV-2-susceptible mouse model using adeno-associated virus (AAV6.2FF)-mediated respiratory delivery of the human ACE2 gene. Viruses 15. https:\/\/doi.org\/10.3390\/v15010085 (2022).","DOI":"10.3390\/v15010085"},{"key":"1355_CR54","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1134\/S0026893322050065","volume":"56","author":"DV Glazkova","year":"2022","unstructured":"Glazkova, D. V. et al. Generation of SARS-CoV-2 mouse model by transient expression of the human ACE2 gene mediated by intranasal administration of AAV-hACE2. Mol. Biol. 56, 705\u2013712 (2022).","journal-title":"Mol. Biol."},{"key":"1355_CR55","doi-asserted-by":"publisher","unstructured":"Tran, B. M. et al. Air-liquid-interface differentiated human nose epithelium: a robust primary tissue culture model of SARS-CoV-2 infection. Int. J. Mol. Sci. 23, https:\/\/doi.org\/10.3390\/ijms23020835 (2022).","DOI":"10.3390\/ijms23020835"},{"key":"1355_CR56","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1038\/s41577-022-00784-3","volume":"23","author":"Y Chen","year":"2023","unstructured":"Chen, Y. et al. Broadly neutralizing antibodies to SARS-CoV-2 and other human coronaviruses. Nat. Rev. Immunol. 23, 189\u2013199 (2023).","journal-title":"Nat. Rev. Immunol."},{"key":"1355_CR57","doi-asserted-by":"publisher","unstructured":"Wu, W. L. et al. Monoclonal antibody targeting the conserved region of the SARS-CoV-2 spike protein to overcome viral variants. JCI Insight 7. https:\/\/doi.org\/10.1172\/jci.insight.157597 (2022).","DOI":"10.1172\/jci.insight.157597"},{"key":"1355_CR58","doi-asserted-by":"publisher","first-page":"998","DOI":"10.1016\/j.immuni.2022.04.003","volume":"55","author":"Z Wang","year":"2022","unstructured":"Wang, Z. et al. Analysis of memory B cells identifies conserved neutralizing epitopes on the N-terminal domain of variant SARS-CoV-2 spike proteins. Immunity 55, 998\u20131012 e1018 (2022).","journal-title":"Immunity"},{"key":"1355_CR59","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.abn3715","volume":"14","author":"KW Ng","year":"2022","unstructured":"Ng, K. W. et al. SARS-CoV-2 S2-targeted vaccination elicits broadly neutralizing antibodies. Sci. Transl. Med. 14, eabn3715 (2022).","journal-title":"Sci. Transl. Med."},{"key":"1355_CR60","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.1126\/science.abj3321","volume":"373","author":"D Pinto","year":"2021","unstructured":"Pinto, D. et al. Broad betacoronavirus neutralization by a stem helix-specific human antibody. Science 373, 1109\u20131116 (2021).","journal-title":"Science"},{"key":"1355_CR61","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/j.chom.2022.10.010","volume":"31","author":"C Dacon","year":"2023","unstructured":"Dacon, C. et al. Rare, convergent antibodies targeting the stem helix broadly neutralize diverse betacoronaviruses. Cell Host Microbe 31, 97\u2013111 e112 (2023).","journal-title":"Cell Host Microbe"},{"key":"1355_CR62","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2022.100510","volume":"3","author":"SI Richardson","year":"2022","unstructured":"Richardson, S. I. et al. SARS-CoV-2 Beta and Delta variants trigger FC effector function with increased cross-reactivity. Cell Rep. Med. 3, 100510 (2022).","journal-title":"Cell Rep. Med."},{"key":"1355_CR63","doi-asserted-by":"publisher","first-page":"1885","DOI":"10.1056\/NEJMoa2102214","volume":"384","author":"SA Madhi","year":"2021","unstructured":"Madhi, S. A. et al. Efficacy of the ChAdOx1 nCoV-19 Covid-19 Vaccine against the B.1.351 Variant. N Engl J Med 384, 1885\u201398 (2021).","journal-title":"N Engl J Med"},{"key":"1355_CR64","doi-asserted-by":"publisher","first-page":"1379","DOI":"10.1038\/s41591-021-01413-7","volume":"27","author":"T Kustin","year":"2021","unstructured":"Kustin, T. et al. Evidence for increased breakthrough rates of SARS-CoV-2 variants ofconcern in BNT162b2-mRNA-vaccinated individuals. Nat. Med. 27, 1379\u20131384 (2021).","journal-title":"Nat. Med."},{"key":"1355_CR65","doi-asserted-by":"publisher","unstructured":"Li, Q. et al. The impact of mutations in SARS-CoV-2 spike on viral infectivity and antigenicity. Cell. https:\/\/doi.org\/10.1016\/j.cell.2020.07.012 (2020).","DOI":"10.1016\/j.cell.2020.07.012"},{"key":"1355_CR66","doi-asserted-by":"publisher","unstructured":"Nguyen, T. H. O., et al. CD8+ T cells specific for an immunodominant SARS-CoV-2 nucleocapsid epitope display high na\u00efve precursor frequency and T cell receptor promiscuity. Immunity. https:\/\/doi.org\/10.1016\/j.immuni.2021.04.009 (2021).","DOI":"10.1016\/j.immuni.2021.04.009"},{"key":"1355_CR67","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2021.110214","volume":"38","author":"KI Wagner","year":"2022","unstructured":"Wagner, K. I. et al. Recruitment of highly cytotoxic CD8(+) T cell receptors in mild SARS-CoV-2 infection. Cell Rep. 38, 110214 (2022).","journal-title":"Cell Rep."},{"key":"1355_CR68","doi-asserted-by":"publisher","first-page":"1764","DOI":"10.1016\/j.immuni.2022.08.008","volume":"55","author":"A Bertoletti","year":"2022","unstructured":"Bertoletti, A., Le Bert, N. & Tan, A. T. SARS-CoV-2-specific T cells in the changing landscape of the COVID-19 pandemic. Immunity 55, 1764\u20131778 (2022).","journal-title":"Immunity"},{"key":"1355_CR69","doi-asserted-by":"publisher","first-page":"e348","DOI":"10.1016\/S2666-5247(22)00036-2","volume":"3","author":"L Guo","year":"2022","unstructured":"Guo, L. et al. SARS-CoV-2-specific antibody and T-cell responses 1 year after infection in people recovered from COVID-19: a longitudinal cohort study. Lancet Microbe 3, e348\u2013e356 (2022).","journal-title":"Lancet Microbe"},{"key":"1355_CR70","doi-asserted-by":"publisher","first-page":"996","DOI":"10.1016\/j.cell.2020.09.038","volume":"183","author":"C Rydyznski Moderbacher","year":"2020","unstructured":"Rydyznski Moderbacher, C. et al. Antigen-specific adaptive immunity to SARS-CoV-2 in acute COVID-19 and associations with age and disease severity. Cell 183, 996\u20131012 e1019 (2020).","journal-title":"Cell"},{"key":"1355_CR71","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2023.104735","volume":"95","author":"AR Schulz","year":"2023","unstructured":"Schulz, A. R. et al. SARS-CoV-2 specific plasma cells acquire long-lived phenotypes in human bone marrow. EBioMedicine 95, 104735 (2023).","journal-title":"EBioMedicine"},{"key":"1355_CR72","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1111\/imr.13115","volume":"309","author":"DC Nguyen","year":"2022","unstructured":"Nguyen, D. C. et al. COVID-19 and plasma cells: is there long-lived protection? Immunol. Rev. 309, 40\u201363 (2022).","journal-title":"Immunol. Rev."},{"key":"1355_CR73","doi-asserted-by":"publisher","unstructured":"Giannotta, G. & Giannotta, N. mRNA COVID-19 vaccines and long-lived plasma cells: a complicated relationship. Vaccines 9. https:\/\/doi.org\/10.3390\/vaccines9121503 (2021).","DOI":"10.3390\/vaccines9121503"},{"key":"1355_CR74","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1016\/j.immuni.2015.06.016","volume":"43","author":"JL Halliley","year":"2015","unstructured":"Halliley, J. L. et al. Long-lived plasma cells are contained within the CD19(-)CD38(hi)CD138(+) subset in human bone marrow. Immunity 43, 132\u2013145 (2015).","journal-title":"Immunity"},{"key":"1355_CR75","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1038\/s41586-021-03738-2","volume":"596","author":"JS Turner","year":"2021","unstructured":"Turner, J. S. et al. SARS-CoV-2 mRNA vaccines induce persistent human germinal centre responses. Nature 596, 109\u2013113 (2021).","journal-title":"Nature"},{"key":"1355_CR76","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1016\/j.immuni.2020.08.001","volume":"53","author":"Y Kato","year":"2020","unstructured":"Kato, Y. et al. Multifaceted effects of antigen valency on B cell response composition and differentiation in vivo. Immunity 53, 548\u2013563 e548 (2020).","journal-title":"Immunity"},{"key":"1355_CR77","doi-asserted-by":"publisher","first-page":"945","DOI":"10.1016\/j.immuni.2022.05.004","volume":"55","author":"D Bhattacharya","year":"2022","unstructured":"Bhattacharya, D. Instructing durable humoral immunity for COVID-19 and other vaccinable diseases. Immunity 55, 945\u2013964 (2022).","journal-title":"Immunity"},{"key":"1355_CR78","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1016\/j.cell.2019.03.016","volume":"177","author":"JG Cyster","year":"2019","unstructured":"Cyster, J. G. & Allen, C. D. C. B Cell responses: cell interaction dynamics and decisions. Cell 177, 524\u2013540 (2019).","journal-title":"Cell"},{"key":"1355_CR79","doi-asserted-by":"publisher","first-page":"1817","DOI":"10.1021\/acschembio.5b00239","volume":"10","author":"NR Bennett","year":"2015","unstructured":"Bennett, N. R., Zwick, D. B., Courtney, A. H. & Kiessling, L. L. Multivalent antigens for promoting B and T cell activation. ACS Chem. Biol. 10, 1817\u20131824 (2015).","journal-title":"ACS Chem. Biol."},{"key":"1355_CR80","doi-asserted-by":"publisher","first-page":"1762","DOI":"10.1038\/s41590-023-01597-9","volume":"24","author":"JF Brooks","year":"2023","unstructured":"Brooks, J. F. et al. Molecular basis for potent B cell responses to antigen displayed on particles of viral size. Nat. Immunol. 24, 1762\u20131777 (2023).","journal-title":"Nat. Immunol."},{"key":"1355_CR81","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-36672-0","volume":"14","author":"A Ferapontov","year":"2023","unstructured":"Ferapontov, A. et al. Antigen footprint governs activation of the B cell receptor. Nat. Commun. 14, 976 (2023).","journal-title":"Nat. Commun."},{"key":"1355_CR82","doi-asserted-by":"publisher","first-page":"730","DOI":"10.1016\/j.cell.2020.09.018","volume":"183","author":"H Yao","year":"2020","unstructured":"Yao, H. et al. Molecular architecture of the SARS-CoV-2 virus. Cell 183, 730\u2013738 e713 (2020).","journal-title":"Cell"},{"key":"1355_CR83","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-019-45461-z","volume":"9","author":"D Christiansen","year":"2019","unstructured":"Christiansen, D. et al. Pre-clinical evaluation of a quadrivalent HCV VLP vaccine in pigs following microneedle delivery. Sci. Rep. 9, 9251 (2019).","journal-title":"Sci. Rep."},{"key":"1355_CR84","doi-asserted-by":"publisher","unstructured":"Cai, J. P. et al. Intranasal boosting with spike Fc-RBD of Wild-Type SARS-CoV-2 induces neutralizing antibodies against omicron subvariants and reduces viral load in the nasal turbinate of mice. Viruses 15. https:\/\/doi.org\/10.3390\/v15030687 (2023).","DOI":"10.3390\/v15030687"},{"key":"1355_CR85","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-023-39402-0","volume":"13","author":"K Tabynov","year":"2023","unstructured":"Tabynov, K. et al. An intranasal vaccine comprising SARS-CoV-2 spike receptor-binding domain protein entrapped in mannose-conjugated chitosan nanoparticle provides protection in hamsters. Sci. Rep. 13, 12115 (2023).","journal-title":"Sci. Rep."},{"key":"1355_CR86","doi-asserted-by":"publisher","DOI":"10.1038\/s41541-024-00857-5","volume":"9","author":"M Xing","year":"2024","unstructured":"Xing, M. et al. An intranasal combination vaccine induces systemic and mucosal immunity against COVID-19 and influenza. NPJ Vaccines 9, 64 (2024).","journal-title":"NPJ Vaccines"},{"key":"1355_CR87","doi-asserted-by":"publisher","first-page":"1865","DOI":"10.1099\/jgv.0.000493","volume":"97","author":"L Earnest-Silveira","year":"2016","unstructured":"Earnest-Silveira, L. et al. Characterization of a hepatitis C virus-like particle vaccine produced in a human hepatocyte-derived cell line. J. Gen. Virol. 97, 1865\u20131876 (2016).","journal-title":"J. Gen. Virol."},{"key":"1355_CR88","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2023.104574","volume":"92","author":"G Deliyannis","year":"2023","unstructured":"Deliyannis, G. et al. Broad immunity to SARS-CoV-2 variants of concern mediated by a SARS-CoV-2 receptor-binding domain protein vaccine. EBioMedicine 92, 104574 (2023).","journal-title":"EBioMedicine"},{"key":"1355_CR89","doi-asserted-by":"crossref","unstructured":"Hierholzer, J. C. & Killington, R. A. Virus isolation and quantitation. Virology Methods Manual, 25\u201346 (Elsevier, 1996).","DOI":"10.1016\/B978-012465330-6\/50003-8"}],"container-title":["npj Vaccines"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41541-025-01355-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41541-025-01355-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41541-025-01355-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,30]],"date-time":"2026-01-30T17:03:30Z","timestamp":1769792610000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41541-025-01355-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,17]]},"references-count":89,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1355"],"URL":"https:\/\/doi.org\/10.1038\/s41541-025-01355-y","relation":{},"ISSN":["2059-0105"],"issn-type":[{"value":"2059-0105","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,17]]},"assertion":[{"value":"4 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Two patents (PCT\/AU2022\/050844 and PCT\/AU2022\/050843) covering the SARS-CoV-2 VLP vaccines and the underlying technology described in this study have been submitted through The University of Melbourne, with D.I.G. and J.T. as co-inventors. C.W.T. and L.-F.W. are co-inventors of a patent on the surrogate virus neutralization test (sVNT) platform. S.R. is an employee of CSL Seqirus. The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"34"}}